GMED
Globus Medical Inc

1,532
Mkt Cap
$8.33B
Volume
1.37M
52W High
$94.93
52W Low
$51.79
PE Ratio
23.80
GMED Fundamentals
Price
$61.66
Prev Close
$61.20
Open
$60.64
50D MA
$59.35
Beta
1.02
Avg. Volume
1.29M
EPS (Annual)
$0.747
P/B
1.94
Rev/Employee
$475,350.00
Loading...
Loading...
News
all
press releases
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +45.00% and +11.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3h ago
News Placeholder
More News
News Placeholder
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?
Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.
Zacks·13h ago
News Placeholder
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Zacks·13h ago
News Placeholder
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Zacks·13h ago
News Placeholder
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Zacks·5d ago
News Placeholder
Globus Medical (GMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
Globus Medical (GMED) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·7d ago
News Placeholder
Ekso Bionics (EKSO) Reports Q3 Loss, Beats Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of +45.45% and +8.11%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?
Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
Zacks·8d ago
News Placeholder
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Zacks·12d ago

Latest GMED News

View

Advertisement|Remove ads.

Advertisement|Remove ads.